Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

CVKD

Cadrenal Therapeutics (CVKD)

Cadrenal Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CVKD
DateTimeSourceHeadlineSymbolCompany
06/12/20244:10PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CVKDCadrenal Therapeutics Inc
06/11/20245:27PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CVKDCadrenal Therapeutics Inc
06/11/20245:25PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CVKDCadrenal Therapeutics Inc
06/03/20249:00AMPR Newswire (US)Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD PatientsNASDAQ:CVKDCadrenal Therapeutics Inc
05/29/20245:27PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CVKDCadrenal Therapeutics Inc
05/23/20249:00AMPR Newswire (US)Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
05/09/20249:00AMPR Newswire (US)Cadrenal Therapeutics Provides First Quarter 2024 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
05/09/20246:23AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CVKDCadrenal Therapeutics Inc
04/11/20244:30PMPR Newswire (US)Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
04/09/20249:00AMPR Newswire (US)Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsNASDAQ:CVKDCadrenal Therapeutics Inc
03/11/20249:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
03/11/20249:00AMPR Newswire (US)Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
03/05/20245:24PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
02/26/20249:00AMPR Newswire (US)Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
02/15/20248:00AMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CVKDCadrenal Therapeutics Inc
02/12/20244:49PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
02/08/20249:00AMPR Newswire (US)Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialNASDAQ:CVKDCadrenal Therapeutics Inc
01/31/20249:00AMPR Newswire (US)Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical ConditionsNASDAQ:CVKDCadrenal Therapeutics Inc
01/24/20249:00AMPR Newswire (US)Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
01/04/20249:00AMPR Newswire (US)Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
12/19/20239:00AMPR Newswire (US)Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price TargetNASDAQ:CVKDCadrenal Therapeutics Inc
12/12/20239:00AMPR Newswire (US)Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and CommercializationNASDAQ:CVKDCadrenal Therapeutics Inc
11/30/20234:15PMPR Newswire (US)Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023NASDAQ:CVKDCadrenal Therapeutics Inc
11/09/20239:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
11/09/20239:00AMPR Newswire (US)Cadrenal Therapeutics Provides Third Quarter 2023 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
11/09/20238:00AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CVKDCadrenal Therapeutics Inc
10/23/20235:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
10/09/20234:15PMPR Newswire (US)Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
09/08/20234:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
09/05/20238:00AMPR Newswire (US)Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology CongressNASDAQ:CVKDCadrenal Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CVKD

Your Recent History

Delayed Upgrade Clock